LYCOTEC, a Cambridge UK based company has published results of the first successful double blind placebo controlled trial on a patented milk serum/protein product which can reduce liver inflammation, and as result of this, reverse metabolic, vascular and tissue parameters, growth of which is associated with age.
The average 5-year-old child in the Western world weighs 15 kg and consumes about 330 ml of milk per day. The average adult weighs 75 kg and consumes about 120 ml of milk, which is 14 times less per 1 kilogram of its body mass than for the child.
For children who do not yet have an efficient immune system, and are in the process of building it up, milk provides not only comprehensive nutrients, but also essential factors in helping them to be protected from infections and accompanying inflammatory damage.
However, with advances in science and medicine we are reaching ages which perhaps are not fully covered by programmes coded in our bodies, and are developing conditions that the majority of the human species had never developed in many thousands of years of their evolution.
There is a growing consensus that behind age related changes – such as rising cholesterol, blood pressure and excessive fat accumulation – are processes of subclinical inflammation. They may start in the digestive tract and in the liver, and then spread to vessels, the brain, skeletal muscles, fat and other tissues and even skin.
To strengthen the body defence in our advanced ages it would seem logical to mobilise those natural sources, which helped us in infancy and childhood. However, consumption of 1 to 2 litres of milk a day is not only impractical for us but also not sustainable for the planet.
To help to solve this problem a team at LYCOTEC, lead by Dr Ivan Petyaev, has developed and patented a new Lycosome technology, which protects proteins responsible for anti-inflammatory properties of the milk, to bypass acidity and digestion of the stomach.
In the published papers the authors reported that this technology could increase 100-fold efficacy in delivery of these milk proteins. This resulted in a reduction of markers of liver inflammation, elevated blood lipids, blood pressure and an improvement in oxygenation of muscles and skin.
This trial demonstrated that the application of Lycosome technology for delivery of milk proteins could be an effective way to reduce subclinical liver inflammation, and present a significant step in the development of sustainable nutritional solutions to controlling ageing from within.